- Home
- ZBH vs ZURA Comparison
ZBH vs ZURA Comparison
Compare ZBH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBH | ZURA |
|---|---|---|
| Founded | 1927 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 407.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBH | ZURA |
|---|---|---|
| Price | $96.15 | $6.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $105.17 | $11.78 |
| AVG Volume (30 Days) | ★ 2.4M | 812.8K |
| Earning Date | 02-10-2026 | 03-24-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.55 | N/A |
| Revenue | ★ $8,231,500,000.00 | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $4.13 | N/A |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $84.59 | $0.97 |
| 52 Week High | $114.44 | $6.88 |
Technical Indicators
Market Signals| Indicator | ZBH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 71.68 | 57.64 |
| Support Level | $90.22 | $5.59 |
| Resistance Level | $97.22 | $6.88 |
| Average True Range (ATR) | 2.58 | 0.49 |
| MACD | 1.26 | -0.03 |
| Stochastic Oscillator | 98.26 | 52.82 |
Price Performance
Historical ComparisonAbout ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.